Health
Pfizer lifts 2026 guidance as cancer, migraine sales offset Covid slide
Pfizer raised its 2026 financial guidance as strong growth in its oncology and migraine businesses helped it weather sharp sales drops in its Covid products. The company reported third-quarter sales and ...
- Published
- (52 min ago)
- Outlet
- Endpoints News
- Section
- Health
- Length here
- Headline and 32-word snippet. The full article is at the source.
More from Endpoints News and around the same time
The biggest conversations in health techTomorrow, I’ll hop on a plane for what has become my favorite day of the year. On Thursday, we’re hosting our second-ever Endpoints Health Tech Day, with a virtual daytime ...Novartis ends BioArctic pact; Two VC firms raise inaugural fundsPlus news about Teva, Ultragenyx and Specific Biologics. Novartis cans BioArctic collab: The Swiss pharma axed its discovery-stage work with the Swedish biotech, which created the Alzheimer’s drug Leqembi. The…Bayer CEO says company is ‘working on’ MFN in the USBayer CEO Bill Anderson said the drugmaker is “working on” a most favored nation agreement, signaling that it is in talks with President Donald Trump’s administration. The German drugmaker was not part ...Merck KGaA to exit CDMO business, divesting US sites to LonzaMerck KGaA is selling its CDMO business to Lonza. The deal covers five manufacturing facilities and about 1,100 employees. While the finer financial details of the pact were kept under wraps, Merck KGaAAbbVie, Brise disclose deal for two preclinical migraine medsAbbVie has agreed to a discovery and commercialization deal with Brise Pharma for two preclinical migraine programs. The Beijing-based partner said Monday the agreement actually stemmed from 2024. An investor relations ...WuXi Biologics, Fresenius partner ahead of biosimilar boomWuXi Biologics and German drugmaker Fresenius have reached one of the largest biosimilar deals to date ahead of what some in the industry have called an upcoming “golden decade” for such products. ...This page holds the headline and a short snippet as published by Endpoints News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
